This question comes up with SKVI:
Why is Skinvisible Pharmaceutical’s (OTCQB: SKVI) so critical?
What is special about it?
In Simple Words:
When it comes to Skinvisible and their Invisicare polymer, this polymer (in simple words) is a substance that binds an active ingredient to the skin to increase the active ingredient’s effectiveness. If you are using it to keep a medicine in place or to keep an antiseptic in place, the better the polymer the more likely the polymer will bind to the skin and make the active ingredient effective.
What makes Skinvisible’s polymer so good is that it is effective up to FOUR HOURS. That’s not just a statement based on their belief. They have scientifically proven it. Here are details from their Invisicare website:
The fourth image above in the lower right hand corner says shows the success after four hours with the polymer. As it says, “4 hours post application the Hand Sanitzer Lotion with Invisicare firmly bound to Stratum Corneum.”
The source of this information is found on the Invisicare website and is taken from (quoting that site) “an excerpt taken from Chapter 4 of the ‘Report of The Scientific Advisory Committee on The Skinvisible® Line of Products’.”
Here is just SOME of the products they currently offer:
ABOVE: Sunless Tanning, Sunscreen and Hand Sanitizer (left to right)
Above: Moisterizer, Antifungal and Atopic Dermatitis (left to right)
Above: Acne Treatment
How is the Invisicare polymer protected?
They have an extensive patent portfolio. This come from their Skinvisible website:
GRANTED PATENTS
United States Patents Granted
United States Patent No.: 8,318,818
Granted: November 27, 2012 (1420 day extension)
Topical composition, topical composition precursor, and methods for manufacturing and using.
United States Patent No.: 7,674,471
Granted: Granted: March 9, 2010 (921 day extension)
Topical composition, topical composition precursor, and methods for manufacturing and using.
United States Patent No.: 6,756,059
Granted: June 29, 2004
Topical composition, topical composition precursor, and methods for manufacturing and using.
United States Invisicare Product Patents Granted
United States Patent No.: 8,299,122
Granted: October 30, 2012
Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition.
United States Patent No.: 8,128,913
Granted: March 6, 2012
Sunscreen composition with enhanced UV-A absorber stability and methods.
United States Patent No.: 6,582,683
Granted: June 24, 2003
Dermal barrier composition.
International Patents Granted
India Patent
Granted: July 26, 2007
Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.
Australia Patent
Granted: June 3, 2008
Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.
China Patent
Granted: July 1, 2009
Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.
Korea Patent
Granted: February 9, 2010
Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.
Hong Kong Patent
Granted: July 27, 2010
Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.
Canada Patent
Granted: February 22, 2011
Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.
European Patent(4)
Granted: September, 2011
Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using.
We will continue our coverage all week. We will look more closely at how this exclusive polymer going to help Kintari.
RECENT ALERTS ON SKINVISIBLE:
John Pentony now represents Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock. John Pentony has signed a contract to as investor relations for Skinvisible, and will be paid up to eleven thousand dollars during the next twelve months should the contract go for twelve months as expected.